MX2021010916A - Inhibidores rad51. - Google Patents

Inhibidores rad51.

Info

Publication number
MX2021010916A
MX2021010916A MX2021010916A MX2021010916A MX2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A MX 2021010916 A MX2021010916 A MX 2021010916A
Authority
MX
Mexico
Prior art keywords
rad51
inhibitors
rad51 inhibitors
directed
represented
Prior art date
Application number
MX2021010916A
Other languages
English (en)
Spanish (es)
Inventor
Joseph VACCA
Casey Cameron Mccomas
Jean- Marc LAPIERRE
Original Assignee
Cyteir Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyteir Therapeutics Inc filed Critical Cyteir Therapeutics Inc
Publication of MX2021010916A publication Critical patent/MX2021010916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2021010916A 2019-03-12 2020-03-12 Inhibidores rad51. MX2021010916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816998P 2019-03-12 2019-03-12
PCT/US2020/022293 WO2020186006A1 (en) 2019-03-12 2020-03-12 Rad51 inhibitors

Publications (1)

Publication Number Publication Date
MX2021010916A true MX2021010916A (es) 2021-10-01

Family

ID=72422797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010916A MX2021010916A (es) 2019-03-12 2020-03-12 Inhibidores rad51.

Country Status (15)

Country Link
US (3) US11247988B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938358B1 (cg-RX-API-DMAC7.html)
JP (1) JP7460649B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210127790A (cg-RX-API-DMAC7.html)
CN (1) CN114072390B (cg-RX-API-DMAC7.html)
AU (1) AU2020235089A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017336A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132987A1 (cg-RX-API-DMAC7.html)
IL (1) IL285889B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010916A (cg-RX-API-DMAC7.html)
PH (1) PH12021552147A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109399SA (cg-RX-API-DMAC7.html)
TW (1) TW202104198A (cg-RX-API-DMAC7.html)
WO (1) WO2020186006A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106284B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014315A1 (en) 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
MX2020002745A (es) 2017-09-11 2020-10-14 Cyteir Therapeutics Inc Inhibidores de rad51.
WO2020186006A1 (en) 2019-03-12 2020-09-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
PH12021552205A1 (en) 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
TW202114662A (zh) 2019-06-21 2021-04-16 美商賽堤爾醫療公司 利用rad51抑制劑治療胰臟癌之方法
EP4108663A1 (en) * 2020-02-19 2022-12-28 Simcere Pharmaceutical Co., Ltd. Substituted aryl compound
WO2023078271A1 (zh) * 2021-11-02 2023-05-11 上海旭成医药科技有限公司 芳香化合物、其制备方法、中间体、药物组合物和应用
WO2023185831A1 (zh) * 2022-03-29 2023-10-05 正大天晴药业集团股份有限公司 含有噻唑环的化合物
CN114736173B (zh) * 2022-05-24 2024-06-11 无锡捷化医药科技有限公司 一种3-(二氟甲基)氧杂环丁烷-3-胺盐酸盐的制备方法
EP4574817A1 (en) * 2023-12-21 2025-06-25 LoQus23 Therapeutics Limited Inhibitory compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6230780A (ja) 1985-04-17 1987-02-09 Ss Pharmaceut Co Ltd 1,7−ナフチリジン誘導体及びこれを含有する薬剤
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
DE69132905T2 (de) 1990-12-06 2002-08-01 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Detektion von Nukleinsäuresequenzen
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US9199979B2 (en) * 2011-02-24 2015-12-01 Nerviano Medical Sciences S.R.L. Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
CN107007597A (zh) 2012-05-31 2017-08-04 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
JP2017100949A (ja) * 2014-04-01 2017-06-08 大日本住友製薬株式会社 5員環ヘテロアリール誘導体
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
WO2016140971A1 (en) 2015-03-02 2016-09-09 The Regents Of The University Of California Novel rad51 inhibitors and uses thereof
US10442817B2 (en) * 2015-06-04 2019-10-15 Drexel University Inhibitors of RAD52 recombination protein and methods using same
WO2019014315A1 (en) * 2017-07-11 2019-01-17 Cyteir Therapeutics, Inc. RAD51 INHIBITORS
MX2020002745A (es) 2017-09-11 2020-10-14 Cyteir Therapeutics Inc Inhibidores de rad51.
WO2020186006A1 (en) 2019-03-12 2020-09-17 Cyteir Therapeutics, Inc. Rad51 inhibitors
PH12021552205A1 (en) 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors

Also Published As

Publication number Publication date
SG11202109399SA (en) 2021-09-29
EP3938358B1 (en) 2024-10-02
CA3132987A1 (en) 2020-09-17
US20240360120A1 (en) 2024-10-31
IL285889B2 (en) 2024-09-01
IL285889B1 (en) 2024-05-01
ZA202106284B (en) 2023-02-22
EP3938358A1 (en) 2022-01-19
IL285889A (en) 2021-10-31
KR20210127790A (ko) 2021-10-22
JP2022525069A (ja) 2022-05-11
EP3938358A4 (en) 2022-12-21
US11247988B2 (en) 2022-02-15
US20200291014A1 (en) 2020-09-17
WO2020186006A1 (en) 2020-09-17
JP7460649B2 (ja) 2024-04-02
BR112021017336A2 (pt) 2021-11-09
US20220259198A1 (en) 2022-08-18
CN114072390B (zh) 2024-06-11
AU2020235089A1 (en) 2021-09-23
US11932636B2 (en) 2024-03-19
PH12021552147A1 (en) 2023-01-04
CN114072390A (zh) 2022-02-18
TW202104198A (zh) 2021-02-01

Similar Documents

Publication Publication Date Title
MX2023004221A (es) Inhibidores de rad51.
PH12021552147A1 (en) Rad51 inhibitors
MX2023000081A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
PH12021553132A1 (en) Methods of using rad51 inhibitors for treatment of pancreatic cancer
PH12021552205A1 (en) Combinations of rad51 and parp inhibitors
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12022550892A1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12019501812A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
MX2020009347A (es) Picolinamidas como fungicidas.
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2021003478A (es) Compuestos utiles como inhibidores de cinasa.
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2020000367A (es) Inhibidores de rad51.
MX375499B (es) Purificación de pleuromutilina.
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.